Literature DB >> 22795502

Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and Lifestyle (VITAL) study.

Cheryl Shih1, James M Hotaling, Jonathan L Wright, Emily White.   

Abstract

PURPOSE: Literature on the chemopreventive role of nonsteroidal anti-inflammatory drugs (NSAIDs) in urothelial carcinoma of the bladder (UC) is conflicting. A recent pooled analysis of 3 cohorts reported regular use of nonaspirin NSAIDs was associated with reduced risk of urothelial carcinoma (UC) among nonsmokers only; however, nonsmokers are a group with a low risk of UC. We examine the association between NSAID use and UC risk.
MATERIALS AND METHODS: Study participants were members of the VITamins and Lifestyle (VITAL) cohort of 77,048 Washington State residents aged 50-76 years who completed a baseline questionnaire in 2000-2002 on NSAID use and cancer risk factors. Ten-year use of aspirin and other NSAIDs was categorized as none, low-use (1-3 d/wk or <4 years), or high-use (≥ 4 d/wk and ≥ 4 years). Incident UC cases were prospectively identified via linkage to a local cancer registry. Hazard ratios (HR) were estimated by multivariate Cox regression.
RESULTS: A total of 385 incident cases of UC were diagnosed over a mean follow-up of 7 years. There was no association with NSAID use and risk of UC. However, the association of use of nonaspirin NSAIDs with UC risk differed by smoking status (P for interaction = 0.02). Specifically, among long-term former smokers (quit ≥ 10 years), nonaspirin NSAID use was associated with a 31% reduction in risk of UC in low-users (HR 0.69, 95% CI 0.46-1.04), and 48% reduction in risk for high-users (HR 0.52, 95% CI 0.24-1.11, P for trend = 0.02).
CONCLUSIONS: Our results show a risk reduction with nonaspirin NSAID use among long-term quitters, a group with significant risk of UC.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aspirin; Cancer prevention; Nonsteroidal anti-inflammatory drugs; Urothelial carcinoma

Mesh:

Substances:

Year:  2012        PMID: 22795502      PMCID: PMC3522785          DOI: 10.1016/j.urolonc.2012.06.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  28 in total

1.  Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.

Authors:  Nancy R Cook; I-Min Lee; J Michael Gaziano; David Gordon; Paul M Ridker; JoAnn E Manson; Charles H Hennekens; Julie E Buring
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

2.  Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study.

Authors:  W Pommer; E Bronder; A Klimpel; U Helmert; E Greiser; M Molzahn
Journal:  Nephrol Dial Transplant       Date:  1999-12       Impact factor: 5.992

Review 3.  Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis.

Authors:  Sarah E Daugherty; Ruth M Pfeiffer; Alice J Sigurdson; Richard B Hayes; Michael Leitzmann; Arthur Schatzkin; Albert R Hollenbeck; Debra T Silverman
Journal:  Am J Epidemiol       Date:  2011-03-02       Impact factor: 4.897

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

6.  Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.

Authors:  Vernon E Steele; Chinthalapally V Rao; Yuting Zhang; Jagan Patlolla; Daniel Boring; Levy Kopelovich; M Margaret Juliana; Clinton J Grubbs; Ronald A Lubet
Journal:  Cancer Prev Res (Phila)       Date:  2009-11

Review 7.  The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation.

Authors:  Seth A Strope; James E Montie
Journal:  J Urol       Date:  2008-05-15       Impact factor: 7.450

8.  Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.

Authors:  Asako Okamoto; Toshiro Shirakawa; Toshinori Bito; Katsumi Shigemura; Katsuyuki Hamada; Akinobu Gotoh; Masato Fujisawa; Masato Kawabata
Journal:  Urology       Date:  2008-01       Impact factor: 2.649

Review 9.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

10.  Non-steroidal anti-inflammatory drugs and bladder cancer prevention.

Authors:  J E Castelao; J M Yuan; M Gago-Dominguez; M C Yu; R K Ross
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more
  7 in total

1.  Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease.

Authors:  Alicia Algaba; Iván Guerra; Angel Castaño; Gema de la Poza; Víctor M Castellano; Montserrat López; Fernando Bermejo
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 2.  [Urological comorbidities in patients with rheumatoid arthritis : literature review].

Authors:  A Friedl; M Mustak; W Höltl; L Erlacher
Journal:  Z Rheumatol       Date:  2013-11       Impact factor: 1.372

3.  Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.

Authors:  Yan Qiao; Tingting Yang; Yong Gan; Wenzhen Li; Chao Wang; Yanhong Gong; Zuxun Lu
Journal:  BMC Cancer       Date:  2018-03-13       Impact factor: 4.430

4.  Retrospective evaluation of the impact of non-oncologic chronic drug therapy on the survival in patients with bladder cancer.

Authors:  Lisa Haimerl; Dorothea Strobach; Hanna Mannell; Christian G Stief; Alexander Buchner; Alexander Karl; Tobias Grimm
Journal:  Int J Clin Pharm       Date:  2021-11-01

5.  Use of nonsteroidal anti-inflammatory drugs and bladder cancer risk: a meta-analysis of epidemiologic studies.

Authors:  Haifeng Zhang; Dongpeng Jiang; Xuedong Li
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

6.  A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma.

Authors:  Deborah W Knapp; Audrey Ruple-Czerniak; José A Ramos-Vara; James F Naughton; Christopher M Fulkerson; Sonia I Honkisz
Journal:  Bladder Cancer       Date:  2016-04-27

7.  Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment.

Authors:  Bo Fan; Alradhi Mohammed; Yuanbin Huang; Hong Luo; Hongxian Zhang; Shenghua Tao; Weijiao Xu; Qian Liu; Tao He; Huidan Jin; Mengfan Sun; Man Sun; Zhifei Yun; Rui Zhao; Guoyu Wu; Xiancheng Li
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.